@article{221e5e23a58d4e26a0de41dcb3c57d9e,
title = "Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma",
abstract = "Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day).",
keywords = "1p/19q codeletion, Anaplastic oligodendroglioma, Autologous stem cell transplant, Temozolomide",
author = "Thomas, {Alissa A.} and Abrey, {Lauren E.} and Robert Terziev and Jeffrey Raizer and Martinez, {Nina L.} and Peter Forsyth and Nina Paleologos and Matthew Matasar and Sauter, {Craig S.} and Craig Moskowitz and Nimer, {Stephen D.} and Deangelis, {Lisa M.} and Thomas Kaley and Sean Grimm and Louis, {David N.} and Cairncross, {J. Gregory} and Panageas, {Katherine S.} and Samuel Briggs and Geraldine Faivre and Mohile, {Nimish A.} and Jayesh Mehta and Philip Jonsson and Debyani Chakravarty and Jianjiong Gao and Nikolaus Schultz and Brennan, {Cameron W.} and Huse, {Jason T.} and Antonio Omuro",
note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",
year = "2017",
month = oct,
day = "1",
doi = "10.1093/neuonc/nox086",
language = "English (US)",
volume = "19",
pages = "1380--1390",
journal = "Neuro-oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "10",
}